Long-term acid reflux drugs linked to severe vitamin deficiencies, case study warns

Two patients walked into their doctors' offices with the same constellation of symptoms: fatigue that wouldn't lift, shortness of breath, a general sense that their bodies were failing them. Blood work revealed something unexpected. Both had severe deficiencies in vitamin B12 and folate—the kind of deficiency that can mimic hemolytic anemia, where the body destroys its own red blood cells faster than it can replace them. What connected them was not genetics or diet, but a medication they'd both been taking for years: proton pump inhibitors, the class of drugs prescribed to millions of people to suppress stomach acid and treat chronic reflux.

Proton pump inhibitors, or PPIs, are among the most widely used medications in the world. They work by blocking the production of stomach acid, providing relief for people with gastroesophageal reflux disease, peptic ulcers, and related conditions. The drugs are effective at what they do, and for many patients, they're genuinely life-changing. But the case report, published in the medical journal Cureus, documents a consequence that doesn't always make it into patient conversations: long-term PPI use can interfere with the body's ability to absorb B vitamins, particularly B12 and folate, which are essential for making healthy red blood cells and maintaining neurological function.

The mechanism is straightforward enough. Stomach acid plays a crucial role in releasing B12 from food proteins so the body can absorb it. Folate absorption also depends on an acidic environment in the digestive tract. When PPIs suppress that acid over months or years, the body loses its ability to extract these vitamins from food, even if someone is eating well. The deficiency doesn't happen overnight. It builds quietly, sometimes for years, until the symptoms become impossible to ignore.

In both cases documented in the report, the patients presented with anemia-like symptoms—fatigue, dyspnea, the physical exhaustion that comes when your blood can't carry enough oxygen. Their lab work showed the telltale signs of combined B12 and folate deficiency: abnormal red blood cells, low hemoglobin, elevated reticulocyte counts that suggested the bone marrow was working overtime trying to compensate. The clinical picture resembled hemolytic anemia so closely that it could have been mistaken for it, except for one crucial detail: the underlying cause was nutritional, not autoimmune or genetic. It was iatrogenic—caused by the treatment itself.

What makes this case report significant is not that it's shocking or unprecedented. Clinicians have known for years that long-term PPI use carries risks. What matters is that it serves as a reminder, a documented warning that gets circulated through medical literature and into the hands of doctors who might otherwise prescribe these medications indefinitely without monitoring. The patients in this report were on PPIs for extended periods—long enough that the deficiency became severe enough to cause symptoms. Neither had been monitored for vitamin levels. Neither had been offered supplementation or alternative treatments.

The forward-looking implication is clear: for patients on prolonged PPI therapy, monitoring matters. B12 and folate levels should be checked periodically. Supplementation should be considered, either through dietary changes or direct supplementation. In some cases, alternative treatments for acid reflux might be worth exploring. The goal isn't to demonize PPIs—they serve an important purpose for many people—but to ensure that the benefits of taking them don't come at the cost of a slow-building nutritional crisis that goes undetected until symptoms force a reckoning.